Literature DB >> 11932280

Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men.

Sundeep Khosla1, Elizabeth J Atkinson, Colin R Dunstan, W M O'Fallon.   

Abstract

Recent studies have shown that estrogen (E) likely plays a dominant role in inhibiting bone resorption in normal elderly men. Because both E and T inhibit osteoclast development and activity, stimulate osteoclast apoptosis, and inhibit osteoblast production of IL-6, it is unclear why T is less potent than E in inhibiting bone resorption in vivo. Osteoprotegerin (OPG) binds to and inactivates RANKL, the final mediator of osteoclastogenesis. In vitro, OPG production is stimulated by E, and preliminary data suggest that T has the opposite effect. Thus, we analyzed serum for OPG levels from a study in which 59 elderly men (mean age, 68 yr) were made acutely hypogonadal using a GnRH agonist and were also placed on an aromatase inhibitor to block conversion of androgens to estrogens. They were studied first under conditions of physiologic E and T replacement, and then randomized to no replacement, replacement with E alone, T alone, or both E and T. E alone resulted in an 18.6 +/- 7.9% (mean +/- SEM) increase in serum OPG levels (P < 0.05), whereas T alone tended to decrease OPG levels (by 10.0 +/- 8.5%; P < 0.05 compared with E alone). Using a two-factor ANOVA model, there was a highly significant T effect (P = 0.006) on decreasing serum OPG levels. Serum TNF-alpha, IL-6, and IL-6 soluble receptor levels increased significantly in the men who had both E and T withdrawn, and the increases in TNF-alpha and IL-6sR were absent in the men treated with either E or T. However, due to the variability in these cytokine measurements, the ANOVA models were not significant for E or T effects. Taken together, these data suggest that in vivo, T decreases OPG levels, whereas E tends to have the opposite effect. These differential effects of E vs. T on OPG production may explain, at least in part, why T has weaker effects than E on inhibiting bone resorption in vivo in humans.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11932280     DOI: 10.1210/jcem.87.4.8397

Source DB:  PubMed          Journal:  J Clin Endocrinol Metab        ISSN: 0021-972X            Impact factor:   5.958


  48 in total

Review 1.  Hormone treatment and muscle anabolism during aging: androgens.

Authors:  E Lichar Dillon; William J Durham; Randall J Urban; Melinda Sheffield-Moore
Journal:  Clin Nutr       Date:  2010-05-07       Impact factor: 7.324

2.  Role of RANK ligand in mediating increased bone resorption in early postmenopausal women.

Authors:  Guitty Eghbali-Fatourechi; Sundeep Khosla; Arunik Sanyal; William J Boyle; David L Lacey; B Lawrence Riggs
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

3.  Changes in biomarkers of inflammation and angiogenesis during androgen deprivation therapy for prostate cancer.

Authors:  Philip J Saylor; Kevin R Kozak; Matthew R Smith; Marek A Ancukiewicz; Jason A Efstathiou; Anthony L Zietman; Rakesh K Jain; Dan G Duda
Journal:  Oncologist       Date:  2012-02-02

Review 4.  Male osteoporosis: new trends in diagnosis and therapy.

Authors:  Hosam K Kamel
Journal:  Drugs Aging       Date:  2005       Impact factor: 3.923

Review 5.  Interleukin-6 in aging and chronic disease: a magnificent pathway.

Authors:  Marcello Maggio; Jack M Guralnik; Dan L Longo; Luigi Ferrucci
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2006-06       Impact factor: 6.053

6.  Serum osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) concentrations in allogeneic stem cell transplant-recipients: a role in bone loss?

Authors:  K Kananen; L Volin; K Laitinen; T Ruutu; M J Välimäki
Journal:  Osteoporos Int       Date:  2005-12-31       Impact factor: 4.507

Review 7.  The pathogenesis, treatment and prevention of osteoporosis in men.

Authors:  Leif Mosekilde; Peter Vestergaard; Lars Rejnmark
Journal:  Drugs       Date:  2013-01       Impact factor: 9.546

8.  Testosterone regulates bone response to inflammation.

Authors:  J P Steffens; B S Herrera; L S Coimbra; D N Stephens; C Rossa; L C Spolidorio; A Kantarci; T E Van Dyke
Journal:  Horm Metab Res       Date:  2014-02-13       Impact factor: 2.936

Review 9.  Men, bone and estrogen: unresolved issues.

Authors:  E S Orwoll
Journal:  Osteoporos Int       Date:  2003-03-04       Impact factor: 4.507

10.  Testosterone replacement in hypogonadal men with angina improves ischaemic threshold and quality of life.

Authors:  C J Malkin; P J Pugh; P D Morris; K E Kerry; R D Jones; T H Jones; K S Channer
Journal:  Heart       Date:  2004-08       Impact factor: 5.994

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.